<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="914">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04377659</url>
  </required_header>
  <id_info>
    <org_study_id>20-185</org_study_id>
    <nct_id>NCT04377659</nct_id>
  </id_info>
  <brief_title>Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection</brief_title>
  <official_title>A Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether the study drug tocilizumab is an effective
      treatment for COVID-19 infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of respiratory failure or death</measure>
    <time_frame>14 days</time_frame>
    <description>The primary endpoint for this cohort is progression of respiratory failure (binary yes/no while hospitalized). Progression of respiratory failure will be defined as a sustained increase in oxygen requirement (FiO2) or need for intubation/mechanical ventilation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Intubation/Mechanical Ventilation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progression of respiratory failure in cohort #1 will be defined as a sustained increase in oxygen requirement or need for intubation/mechanical ventilation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Respiratory Support</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In cohort #2 progression of respiratory failure will be defined as a need for increasing respiratory support (e.g. FiO2 or PEEP)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Participants will receive Tocilizumab 8 mg/kg i.v. at enrollment. Dose will be capped at 800 mg per infusion. If there is no improvement or toxicity, a second dose can be given 24 hrs to 5 days later.</description>
    <arm_group_label>Intubation/Mechanical Ventilation</arm_group_label>
    <arm_group_label>Respiratory Support</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient or designated proxy willing and able to provide informed consent prior to
             enrollment in the study.

          -  COVID-19 PCR positive on nasopharyngeal swab

          -  Aged &gt;/= 18 years old

          -  Patient hospitalized with newly diagnosed documented severe COVID-19 infection: with
             respiratory rate &gt;/= 30 breaths/min OR peripheral capillary oxygen saturation (SpO2) &lt;
             93% on room air for nonintubated pts.

          -  Fever of 38.5 C or suspected respiratory infection

          -  IL-6 level &gt;/= 80 pcg/ml

          -  Cohort #1 - non intubated Cohort #2 - intubated

          -  Women of childbearing potential must have a negative serum or urine pregnancy test

          -  Patients receiving ongoing steroid therapy are eligible

          -  Patients will be allowed to receive concurrent or sequential treatment with remdesivir

        Exclusion Criteria:

          -  Patients with uncontrolled systemic fungal and bacterial infections

          -  Patients with latent tuberculosis

          -  Patients with known hypersensitivity to tocilizumab or any component of the
             formulation

          -  Concurrent initiation of steroid therapy is not allowed

          -  Patients with uncrontroled malignant disease, with a life expectancy of 3 months or
             less
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boglarka Gyurkocza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boglarka Gyurkocza, MD</last_name>
    <phone>646-608-3768</phone>
    <email>gyurkocb@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ann Jubowski, MD</last_name>
    <phone>646-608-3782</phone>
    <email>jakubowa@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boglarka Gyurkocza, MD</last_name>
      <phone>646-608-3768</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>August 20, 2020</last_update_submitted>
  <last_update_submitted_qc>August 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVD-19</keyword>
  <keyword>Tocilizumab</keyword>
  <keyword>Respiratory infection</keyword>
  <keyword>20-185</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

